Custom gene capture and next-generation sequencing to resolve discordant ALK status by FISH and IHC in lung adenocarcinoma

Journal of Thoracic Oncology

Volumn 11, Issue 11, 2016, Pages 1891-1900

  Jang, Jin Sung ^a   Wang, Xiaoke ^a   Vedell, Peter T ^a   Wen, Ji ^b   Zhang, Jinghui ^b   Ellison, David W ^b   Evans, Jared M ^a   Johnson, Sarah H ^a   Yang, Ping ^a   Sukov, William R ^a   Oliveir, Andre M ^a   Vasmatzis, George ^a   Sun, Zhifu ^a   Jen, Jin ^a   Yi, Eunhee S ^a  

^a MAYO CLINIC   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

ALK; Discordant; FISH; IHC; Lung; NGS

Indexed keywords

ANTIBODY; DNA; EZRIN; KINESIN 5; MICROTUBULE ASSOCIATED PROTEIN 4; PROTEIN TYROSINE KINASE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTOME; ANAPLASTIC LYMPHOMA KINASE;

AP2 ASSOCIATED KINASE 1 GENE; ARTICLE; BACULOVIRAL AIP REPEAT CONTAINING 6 GENE; CONTROLLED STUDY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENE FUSION; GENE REARRANGEMENT; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; HUNTINGTON INTERACTING PROTEIN 1 GENE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; NEXT GENERATION SEQUENCING; ONCOGENE RET; PRIORITY JOURNAL; RNA SEQUENCE; STAPHYLOCOCCAL NUCLEASE AND TUDOR DOMAIN CONTAINING 1 GENE; TRANSCRIPTOMICS; ADENOCARCINOMA; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PROCEDURES;

ADENOCARCINOMA; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84995976636     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.06.001     Document Type: Article

References (36)

1. Chihara D, Suzuki R. More on crizotinib. N Engl J Med. 2011;364:776-777 [author reply 778].
2. Yoshida A, Tsuta K, Nitta H, et al. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule- A ssociated protein-like 4- A naplastic lymphoma kinase-positive lung adenocarci-nomas. J Thorac Oncol. 2011;6:1677-1686.
3. Murakami Y, Mitsudomi T, Yatabe Y. A Screening method for the ALK fusion gene in NSCLC. Front Oncol. 2012;2:24.
4. Peled N, Palmer G, Hirsch FR, et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012;7:e14-e16.
5. Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, et al. Fluorescence in situ hybridization, immunohistochem-istry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist. 2015;20:316-322.
6. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013;31:1039-1049.
7. Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20:1479-1484.
8. Ross JS, Cronin M. Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol. 2011;136:527-539.
9. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18:382-384.
10. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378-381.
11. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol. 2011;6:459-465.
12. Asmann YW, Hossain A, Necela BM, et al. A novel bioin-formatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines. Nucleic Acids Res. 2011;39:e100.
13. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754-1760.
14. Novocraft. Novoalign: powerful tool designed for mapping of short reads onto a reference genome from Illumina, Ion Torrent, and 454 NGS platforms. http://www.novocraft. com/products/novoalign/. Accessed July 17, 2016.
15. Broad Institute. Picard: a set of tools (in Java) for working with next generation sequencing data in the BAM format. https://broadinstitute.github.io/picard/. Accessed July 17, 2016.
16. Wang J, Mullighan Cg, Easton CG, et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods. 2011;8:652-654.
17. Karolchik D, Hinrichs AS, Kent WJ. The UCSC Genome Browser. Curr Protoc Bioinformatics. 2012; Chapter 1: Unit 1.4.
18. Drucker TM, Johnson SH, Murphy SJ, Cradic KW, Therneau TM, Vasmatzis G. BIMA V3: an aligner customized for mate pair library sequencing. Bioinformatics. 2014;30:1627-1629.
19. Murphy SJ, Aubry MC, Harris FR, et al. Identification of independent primary tumors and intrapulmonary me-tastases using DNA rearrangements in non-small-cell lung cancer. J Clin Oncol. 2014;32:4050-4058.
20. Vasmatzis G, Johnson SH, Knudson RA, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012;120:2280-2289.
21. Boland JM, Jang JS, Li J, et al. MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol. 2013;8:574-581.
22. Lantuejoul S, Rouquette I, Blons H, et al. French multi-centric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas. Eur Respir J. 2015;46: 207-218.
23. von Laffert M, Stenzinger A, Hummel M, et al. ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making. Lung Cancer. 2015;90:465-471.
24. von Laffert M, Warth A, Penzel R, et al. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. J Thorac Oncol. 2014;9:1685-1692.
25. Kim H, Yoo SB, Choe JY, et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a com-parison of fluorescence in situ hybridization and chro-mogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol. 2011;6:1359-1366.
26. McLeer-Florin A, Moro-Sibilot D, Melis A, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol. 2012;7:348-354.
27. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16: 1561-1571.
28. Martinez P, Hernández-Losa, Montero MÁ, et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PloS One. 2013;8:e52261.
29. Paik JH, Choi CM, Kim H, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer. 2012;76: 403-409.
30. Sholl LM, Weremowicz S, Gray SW, et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol. 2013;8:322-328.
31. Minca EC, Portier BP, Wang Z, et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn. 2013;15:341-346.
32. Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016;374:54-61.
33. Fang DD, et al. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. J Thorac Oncol. 2014;9:285-294.
34. Hong M, Kim RN, Song JY, et al. HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma. J Thorac Oncol. 2014;9:419-422.
35. Ou SH, Klempner SH, Klempner SJ, et al. Identification of a novel HIP1-ALK fusion variant in non-small-cell lung cancer (NSCLC) and discoveryofALK I1171 (I1171N/S)mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. J Thorac Oncol. 2014;9:1821-1825.
36. Jang JS, Lee A, Livanage H, et al. Common oncogene mutations and novel SND1-BRAF transcript fusion in lung adenocarcinoma from never smokers. Sci Rep. 2015;5: 9755.